Figure 1 | Scientific Reports

Figure 1

From: The cyclophilin inhibitor NIM-811 increases muscle cell survival with hypoxia in vitro and improves gait performance following ischemia–reperfusion in vivo

Figure 1

Effects of NIM-811 treatment on ischemic human myoblasts. Ischemic Human myoblasts were treated with (0–20 μM) NIM-811 for 2 h following the exposure to hypoxia for 6 h. Data shown are for cell viability measured by MTS assay (A) and cell toxicity in different groups as determined by LDH assay (B). Data are expressed as mean ± SD (n = 6). ****P = 0.0001, ***P = 0.0005, **P = 0.0022 and *P = 0.01.

Back to article page